You are here
Practical considerations in first-line treatment of mCRPC
Professor Noel W Clarke, Salford Royal Hospital and The Christie, Manchester presents the case of a 58 year old man with asymptomatic adenocarcinoma of the prostate (cT3 Gleason) and metastases initially treated with androgen ablation as monotherapy. After a first decline of prostate-specific antigen (PSA), PSA levels rise and a progressive metastatic castrate resistant prostate cancer developed. The question is how to treat this patient: continuing androgen deprivation therapy (ADT), ADT plus bicalutamide, novel androgen targeting agents or docetaxel?